US Stock MarketDetailed Quotes
PEPG PepGen
- 2.300
- -0.120-4.96%
Close Jan 17 16:00 ET
- 2.290
- -0.010-0.43%
Post 20:01 ET
74.97MMarket Cap-0.77P/E (TTM)
2.445High2.300Low131.86KVolume2.390Open2.420Pre Close310.29KTurnover0.85%Turnover RatioLossP/E (Static)32.60MShares19.29852wk High0.55P/B35.61MFloat Cap2.30052wk Low--Dividend TTM15.48MShs Float20.000Historical High--Div YieldTTM6.00%Amplitude2.300Historical Low2.353Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
PepGen Stock Forum
PepGen Announces Clinical Hold in the U.S. on Ind Application to Initiate Connect2-Edo51 Phase 2 Study of Pgn-Edo51 for Duchenne Muscular Dystrophy
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
Monday, 16th December at 8:00 am
-Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled-
PepGen Inc. (NASDAQ: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Positive
▪️PGN-EDO51 achieved mean exon skipping levels of 2.15% after three months at 5 mg/kg dose
▪️Mean muscle-adjusted dystrophin level increased by 0.70% from baseline
▪️Mean absolute dystrophin level increased by 0.26% from baseline
▪️The 5 mg/kg dose was well-tolerated with no discontinu...
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the first patient has been dosed in its CONNECT1-EDO51 Phase 2, open-label multiple ascending dose (MAD) clinical trial evaluating PGN-EDO51 for the ...
Benzinga· 5 mins ago
No comment yet